亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Proteasome Inhibitors as Steroid Therapy Boosters

技術優勢
FDA approvedMultiple diseases can be treatedMultimodal mechanism of action
詳細技術說明
Novel therapy for cancer and other proliferative disorders that relies on the use of an FDA-approved proteasome inhibitor #therapeutics #anti-inflammatory
*Abstract

Northwestern researchers have developed a novel therapeutic strategy to improve glucocorticoid therapy. While glucocorticoids find application in treating various proliferative and inflammatory disorders, many patients develop resistance over the course of treatment. It has been shown that resistance to glucocorticoids is mediated by degradation of glucocorticoid receptors (GRs) during treatment. This novel therapeutic strategy developed by Prof. Budunova and colleagues, aims to prevent GR degradation by co-administration of glucocorticoids with an FDA-approved proteasome inhibitor. Interestingly, administration of this proteasome inhibitor also increases expression of GR proteins and this multimodal mechanism of action could ensure that patients become and stay glucocorticoid sensitive. This novel treatment methodology is expected to improve quality of life and treatment outcomes for patients with diseases such as asthma, psoriasis and several types of blood cancers. 

*Inventors
Irina Budunova* Alexander Yemelyanov
*Publications
Lesovaya E, Yemelyanov A, Krisanov K, Popa A, Belitsky G, Yakubovskaya M, Gordon LI, Rosen ST, Budunova I (2013) Combination of a Selective Activator of the Glucocorticoid Receptor Compound A with a Proteasome Inhibitor as a Novel Strategy for Chemotherapy of Hematologic Malignancies, Cell Cycle, 12: 133-144.
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備